INTRODUCTION
============

Leptomeningeal disease (LMD) is a fatal complication of non-Hodgkin lymphoma (NHL); therefore, early and accurate diagnosis of LMD is important for the management of NHL. Although conventional cytomorphology is considered as the standard method for the diagnosis of LMD, its utility is limited owing to a low sensitivity with a false-negative rate of 20-60% \[[@B1][@B2]\]. Flow cytometry (FCM) has been used for rapid and sensitive diagnosis of various hematologic malignancies \[[@B3][@B4]\]. FCM analysis has also been demonstrated as an excellent diagnostic tool for detecting leukemia and lymphoma cells in various body fluids \[[@B5][@B6]\].

The utility of FCM for detecting LMD in cerebrospinal fluid (CSF) has also been evaluated in some previous studies, showing promising results \[[@B3][@B7]\]. However, the techniques are tricky owing to the low cell counts, high proportion of non-viable cells in CSF, and necessity for implementing multi-color FMC antibodies. Furthermore, clinical testing methods have not been standardized yet. Because the testing was validated only in a limited number of clinical cohorts, the method and its clinical implications should be further validated in various clinical settings.

In the present study, we explored the clinical usefulness of FCM for the diagnosis of LMD in a series of Korean NHL patients in comparison with the traditional cytology method. In addition, we analyzed the prognostic effect of LMD confirmed by FCM.

METHODS
=======

1. Patient enrollment
---------------------

CSF specimens were obtained in patients with clinically suspected LMD (headache, mental change, paralysis and/or other neurologic sign and symptoms) or high risk diseases (Burkitt lymphoma or multiple metastases of primary tumors) from March 2013 to May 2014 at Samsung Medical Center in Seoul, Korea. For each specimen, cytomorpholgical and FCM analyses were conducted. A total of 55 samples from 30 patients, including 26 males and 4 females (mean age: 51 yr) were analyzed by using FCM, and 47 of them were also analyzed by cytomorphology in parallel. Eight samples were collected at initial work-up, and the others were obtained during follow-up periods. Diffuse large B cell lymphoma (DLBCL) was the most common neoplasm analyzed, and cases of other rare lymphomas including extranodal NK/T cell lymphoma (ENKTL), anaplastic large cell lymphoma (ALCL) and Burkitt lymphoma (BL) were also included ([Supplemental Data Table 1](#S1){ref-type="supplementary-material"}). The number of CD45-positive cells acquired by the FCM instrument ranged from 387 to 1,568,515.

The medical records were reviewed in detail for all cases of FCM and cytomorphology to analyze overall survival (OS). The current study was based on an analysis of routine clinical test results with patients\' consent, and the approval of institutional review board was waived.

2. Flow cytometric analysis of lymphoma cells
---------------------------------------------

FCM analysis was done on the FACSCantoII flow cytometer (Becton Dickinson, San Jose, CA, USA) and the Kaluza software (Beckman Coulter, Brea, CA, USA). Compensation matrix was calculated by using BD CompBead particles (Becton Dickinson) and the compensation setup tool in BD FACSDiva software. The minimum white blood cell (WBC) count in CSF was 1×10^6^/L (1-1,530×10^6^/L).

For mature B-cell malignancy, 7-aminoactinomycin D (7-AAD) and a combination of antibodies including CD45-allophycocyanin-cyanine7 (APC-Cy7), CD19-APC, surface kappa-fluorescein isothiocyanate (FITC), and surface lambda-phycoerythrin (PE) were used. The criteria for determining the results were according to previous literatures \[[@B7][@B8][@B9]\] and as follows: (i) positive; ≥10 B-cells with a kappa/lambda (K/L) ratio of \>4 or \<0.5, (ii) negative: B-cells with a K/L ratio between 0.5 and 4, and (iii) equivocal; \<10 B-cells with a K/L ratio of \>4 or \<0.5. For mature T- or NK-cell neoplasms, we selected surface markers according to the immunophenotypes of primary tumors characterized by immunohistochemistry or FCM. 7-AAD dye was used to select the viable cells \[[@B10]\]. A typical gating strategy is shown in [Supplemental Data Fig. 1](#S2){ref-type="supplementary-material"}. All monoclonal antibodies were from Becton Dickinson.

3. Cytomorphology and CSF analysis
----------------------------------

CSF samples were processed within several hours of collection and interpreted by a cytopathologist blinded to the FCM results. Liquid-based cytology (LBC) methods and Papanicolaou stain were used in the cytomorphological analysis as previously described \[[@B11]\]. Results were reported as negative, positive, and equivocal for lymphoma on the basis of cellular morphology. Lymphocytes or abnormal cells with abnormal nuclear-cytoplasmic ratios and irregular nuclear morphologies were categorized as \"equivocal\", which cannot be clearly categorized as \"positive\" \[[@B12]\]. WBC count was obtained by manual differential counting (100 WBCs), and protein and glucose levels were measured (COBAS Integra800, Roche Diagnostics, Mannheim, Germany).

4. Statistical analysis
-----------------------

The Mann-Whitney test was used to evaluate the difference of CSF protein, glucose, and WBC levels according to results of FCM or cytomorphology. A kappa value was calculated to investigate concordance rates. Kappa values over 0.8 were considered as good agreement. OS (Kaplan-Meier method) of DLBCL in FCM positive and FCM negative or equivocal cases was measured to analyze the prognostic effect of FCM-positive cases from the time of lymphoma diagnosis to death or last follow-up. A *P* value \<0.05 was considered statistically significant. Statistical analysis was performed by using the PASW Statistics 20.0 software (IBM, Armonk, NY, USA).

RESULTS
=======

Fourteen (25.5%) of the 55 samples analyzed by FCM were positive, whereas only six (12.8%) of the 47 samples examined by cytomorphology were positive. All six cytomorphologically positive cases had positive results by FCM, while eight samples from seven patients were determined as positive by FCM but negative or equivocal by cytomorphology ([Table 1](#T1){ref-type="table"}). FCM had lower rates of equivocal results than cytomorphology (2/55 vs. 7/47), and the overall concordance between FCM and cytomorphology was 70.2% (kappa value=0.377, *P*\<0.001). The low concordance rate was due to the low positive rates in cytomorphology (positive by FCM and negative by cytomorphology). The types of lymphoma in the positive cases are shown in [Table 2](#T2){ref-type="table"}.

The clinical characteristics of discrepant cases that were positive by FCM and negative/equivocal by cytomorphology are summarized in [Table 3](#T3){ref-type="table"}. Among these seven patients, four (patient no. 1, 5, 9, and 11) had history of LMD, and their CSF samples were obtained during treatment of LMD. Patients 1 and 9 were initially positive by FCM and equivocal/negative by cytomorphology but were found to be positive by cytomorphology later in the follow-up study. The CD45-positive cells ranged from 636 to 94,258 in these discrepant cases.

The clinical characteristics of other discrepant cases are summarized in [Table 4](#T4){ref-type="table"}. Patients 3, 23, and 26 were negative by FCM and equivocal by cytomorphology, while patients 13 and 20 were equivocal by FCM and negative by cytomorphology. All patients except patient 13 had histories of LMD (samples were obtained during treatment). The CD45-positive cells ranged from 437 to 12,349 in these discrepant cases. CSF protein and WBC levels were significantly higher in positive samples (determined by FCM) compared with negative samples, while CSF glucose levels were not significantly different ([Table 5](#T5){ref-type="table"}).

There was a trend that DLBCL cases positive by FCM have worse prognosis than DLBCL cases negative by FCM, but it did not reach statistical significance (*P*=0.139) probably owing to the small number of cases ([Fig. 1](#F1){ref-type="fig"}).

DISCUSSION
==========

The clinical significance of FCM for the detection of LMD has been evaluated in several studies thus far. In general, FCM has been found to be more sensitive compared with cytomorphology \[[@B6][@B7][@B13][@B14]\]. For example, Di Noto et al. \[[@B14]\] reported positive rates of 26% and 9.5% by FCM and cytomorphology, respectively, which are comparable to the present findings.

The clinical implication of patients who were positive by FCM and negative by cytomorphology has been evaluated in many studies \[[@B13][@B14][@B15][@B16]\]. Benevolo et al. \[[@B16]\] reported a higher risk of central nervous system (CNS) progression in such FCM-positive cases compared with those negative by both FCM and cytomorphology (hazard ratio=8.16). Likewise, Sancho et al. \[[@B17]\] reported a higher CNS relapse or progression rate in such FCM-positive cases compared with those negative by both methods (13% vs. 2.4%, *P*=0.04). Although our study did not show the adverse OS in cases which were positive by FCM, Hegde et al. \[[@B12]\] showed a high incidence of occult LMD (11 of 55 patients) using FCM in newly diagnosed non-aggressive B-cell lymphomas and an association with multiple metastasis of lymphoma. Bernstein et al. \[[@B18]\] suggested that methods can be used to detect subclinical CNS at diagnosis, such as using flow cytometry, and to develop better treatment strategies for patients with subclinical CNS. Thus, the use of FCM for high-risk patients at diagnosis and close follow-up or reevaluation is recommended in cases of occult LMD \[[@B13][@B14][@B15][@B16][@B19]\].

Although the proportion is low, cases that are positive by cytomorphology and negative by FCM may also deserve special attention from clinicians. Bromberg et al. \[[@B15]\] reported that these patients had higher frequency of clinical symptoms and pleocytosis and poorer progression-free survival compared with patients who were positive by FCM only. Since false-negative results may occur during specimen processing (inadequate storage temperature or prolonged storage) or owing to the presence of heterogeneous population (high proportion of normal lymphocyte with minor lymphoma cells) \[[@B20]\], the implementation of cytomorphology in conjunction with FCM could be recommended \[[@B13][@B15]\].

A major problem with the clinical use of FCM is the lack of standardized guidelines for sample preparation, antibody panel, interpretation criteria, and others. Moreover, sufficient amounts of CSF samples cannot be obtained easily, and the low volume and paucity of cells makes it difficult to interpret the results of FCM. Some efforts have been made to overcome these problems \[[@B19]\]. For example, multi-color FCM methods using three or more antibodies and the acquisition of sufficient number of CD45-positive cells in combination with viability selection have proven to increase sensitivity and reliability \[[@B7][@B21][@B22][@B23][@B24]\]. Cesana et al. \[[@B7]\] reported that the diagnostic accuracy of FCM could be significantly improved by acquiring more than 220 CD45-positive cells.

In conclusion, we have evaluated the use of FCM in CSF samples from patients clinically suspected of having LMD. We observed the higher prevalence of LMD by FCM than by cytomorphology. Although we did not observe an adverse prognostic effect of LMD determined by FCM, further studies would be needed to evaluate the diagnostic usefulness of FCM.
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###### Supplemental Data Table 1

Histology and primary sites of 30 patients

###### Supplemental Data Fig. 1

Gating strategy of flow cytometry. (A) A case of extranodal marginal zone lymphoma (Patient 6). Viable lymphocytes with negative 7-AAD (7-Aminoactinomycin D) staining and positive CD45 expression were selected. CD19-positive populations with light chain restriction were considered as malignant B-cells (red color). (B) A case of extranodal NK/T cell lymphoma (Patient 9). After gating on the population with negative 7-AAD and positive CD45 staining, surface CD3-negative and CD56-positive cells were identified (red color). (C) A case of CD30-positive anaplastic large cell lymphoma (ALCL) (Patient 10). Malignant cells with CD30-positive, CD3-negative and CD14-negative immunophenotype.

![Overall survival in cases with diffuse large B cell lymphoma according to the results of flow cytometry (FCM).](alm-36-209-g001){#F1}

###### Comparison of flow cytometry and cytomorphology in cerebrospinal fluid from suspected cases of leptomeningeal diseases

![](alm-36-209-i001)

  FCM         Cytomorphology                  
  ----------- ---------------- ---- ---- ---- ----
  Positive    6                5    3    \-   14
  Negative    \-               27   4    8    39
  Equivocal   \-               2    \-   \-   2
  Total       6                34   7    8    55

Abbreviations: FCM, flow cytometry; NA, not available.

###### Positive cases according to types of lymphoma

![](alm-36-209-i002)

                                                    Positive           
  ------------------------------------------------- ------------------ ----------------
  Anaplastic large B-cell lymphoma                  1                  1
  Burkitt lymphoma                                                     
  Diffuse large B cell lymphoma                     9                  4
  Extranodal marginal zone lymphoma                 1                  
  Extranodal NK/T cell lymphoma                     2                  1
  Mature T cell neoplasm, not otherwise specified   1                  
                                                    14 (11 patients)   6 (5 patients)

###### Summary of discrepant cases that were positive by FCM and negative/equivocal by cytomorphology

![](alm-36-209-i003)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient-sample   Age\   Sex   Histology                                  WBC count\   FCM   CM   Reason for request                                        IT-CTx         Positive in previous study   Positive in f/u study   Imaging study
                   (yr)                                                    (×10^6^/L)                                                                                                                                            
  ---------------- ------ ----- ------------------------------------------ ------------ ----- ---- --------------------------------------------------------- -------------- ---------------------------- ----------------------- ----------------------------------------
  1-1              45     F     DLBCL (neck LN)                            40           P     E    f/u of LMD, brain, breast metastasis mental change        Yes            Yes (by CM)                  Yes (by CM)             1 month f/u PET: not evident LMD

  1-2                                                                      2            P     N    3 days after                                              Yes            Yes (by CM)                  Yes (by CM)             

  3-3              46     M     DLBCL (brain)                              1            P     N    Lower extremity weakness, dysuria                         Yes            Yes (by CM)                  No                      

  5                53     M     DLBCL (neck LN)                            18           P     N    f/u of recurred DLBCL (nasal cavity), diplopia            Yes            No                           No                      Brain MRI: skull base enhancement

  6^\*^            51     M     EMZL (lung)                                5            P     E    Brain imaging work-up -- brain involvement                Yes            No                           No                      Brain MRI: both cavernous

  7^\*^            66     M     Mature T cell neoplasm (small intestine)   1            P     N    HLH, BM involvement                                       No (expired)   No                           No                      Brain CT: not evident

  9                48     M     ENKTL (nasal cavity)                       5            P     E    f/u of recurred ENKTL (liver, BM) visual disturbance      Yes            No                           Yes (by CM)             Orbit MRI: LMD

  11               34     M     DLBCL (brain)                              1            P     N    f/u of recurred (nasal cavity, brain) DLBCL, f/u of LMD   Yes            Yes (by CM)                  No                      Brain MRI: periventricular enhancement
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\*^Initial work-up of primary hematologic malignancy.

Abbreviations; BM, bone marrow; CT, computed tomography; CM, cytomorphology; DLBCL, diffuse large B cell lymphoma; E, equivocal; EMZL, extranodal marginal zone lymphoma; ENKTL, extranodal NK/T cell lymphoma; FCM, flow cytometry; F, female; f/u, follow up; HLH, hemophagocytic lymphohistiocytosis; IT-CTx, intrathecal chemotherapy; LMD, leptomeningeal disease; LN, lymph node; M, male; N, negative; NA, not available; P, positive; PET, positron emission tomography; MRI, magnetic resonance imaging.

###### Summary of other cases showing discrepant results

![](alm-36-209-i004)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient-sample   Age\   Sex   Histology                           WBC count (×10^6^/L)   FCM   CM   Reason for request                                   IT-CTx   Positive in previous study   Positive in f/u study   Imaging study
                   (yr)                                                                                                                                                                                                  
  ---------------- ------ ----- ----------------------------------- ---------------------- ----- ---- ---------------------------------------------------- -------- ---------------------------- ----------------------- -------------------------------------------------------------
  3-2              46     M     DLBCL (brain)                       1                      N     E    f/u of LMD                                           Yes      Yes (by CM, FCM)             No                      MRI: persistent diffuse leptomeningeal abnormal enhancement

  3-4                                                               1                      N     E    10 days after                                        Yes      Yes (by CM, FCM)             No                      

  13               58     M     Burkitt lymphoma (terminal ilium)   1                      E     N    Initial work up                                      Yes      No                           No                      No evidence (CT, MRI)

  20               25     F     DLBCL (stomach)                     1                      E     N    f/u of LMD seizure, altered mentality                Yes      Yes (by CM)                  No                      MRI: multifocal brain involvement

  23               53     M     DLBCL (brain)                       4                      N     E    f/u of multiple metastasis gait/visual disturbance   No       Yes (by CM)                  No                      MRI: brain involvement

  26               76     M     DLBCL (brain)                       48                     N     E    f/u of recurred CNS DLBCL neck pain                  No       Yes (by CM)                  No                      MRI: diffuse leptomeningeal enhancement
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations; CNS, central nervous system; CT, computed tomography; CM, cytomorphology; DLBCL, diffuse large B cell lymphoma; E, equivocal; FCM, flow cytometry; F, female; f/u, follow up; IT-CTx, intrathecal chemotherapy; LMD, leptomeningeal disease; M, male; MRI, magnetic resonance imaging.

###### Comparison of CSF glucose, protein, and white blood cell levels between positive and negative samples

![](alm-36-209-i005)

                                Flow cytometry                          
  ----------------------------- -------------------- ------------------ -------
  Glucose (mg/dL)               89.2±31.7 (n=13)     89.8±28.2 (n=31)   0.827
  Protein (mg/dL)               69.1±84.0 (n=13)     23.4±21.8 (n=31)   0.037
  White blood cell (×10^6^/L)   139.4±420.0 (n=13)   3.36±9.3 (n=28)    0.002

Data are expressed as mean±SD.

^\*^Mann-Whitney test.

Abbreviation: CSF, cerebrospinal fluid.
